Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.77 USD | -4.22% | +6.24% | +56.39% |
May. 01 | Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 | |
May. 01 | Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M | MT |
Business Summary
Number of employees: 100
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Small Molecule Therapeutics
56.2
%
| 31 | 61.1 % | 46 | 56.2 % | +47.89% |
License Revenue
43.8
%
| 20 | 38.9 % | 36 | 43.8 % | +81.16% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 51 | 100.0 % | 83 | 100.0 % | +60.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jack Bailey
CEO | Chief Executive Officer | 59 | 20-03-11 |
John Umstead
DFI | Director of Finance/CFO | - | 17-12-31 |
Rajesh K. Malik
CTO | Chief Tech/Sci/R&D Officer | 65 | 14-06-30 |
Terry Murdock
COO | Chief Operating Officer | 64 | 17-08-02 |
Investor Relations Contact | 54 | 21-01-03 | |
Monica Thomas
HRO | Human Resources Officer | - | 23-05-21 |
Mark Avagliano
PRN | Corporate Officer/Principal | 48 | 19-07-29 |
Andrew Beelen
PRN | Corporate Officer/Principal | - | - |
Andrew Perry
PRN | Corporate Officer/Principal | 51 | 21-08-01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Muir
BRD | Director/Board Member | 65 | 15-08-31 |
Cynthia Flowers
BRD | Director/Board Member | 64 | 18-06-06 |
Norman Sharpless
FOU | Founder | 57 | 08-05-18 |
Alicia Secor
BRD | Director/Board Member | 62 | 21-06-16 |
Garry Nicholson
CHM | Chairman | 69 | 18-09-11 |
Jack Bailey
CEO | Chief Executive Officer | 59 | 20-03-11 |
Jacks Lee
BRD | Director/Board Member | 60 | 22-06-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 52,308,057 | 46,627,576 ( 89.14 %) | 26,666 ( 0.0510 %) | 89.14 % |
Company contact information
G1 Therapeutics, Inc.
700 Park Offices Drive Suite 200
27709, Research Triangle Park
+919 213 9835
http://www.g1therapeutics.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.39% | 249M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- GTHX Stock
- Company G1 Therapeutics, Inc.